Suppr超能文献

窖蛋白-1 介导的转胞吞作用在脂质体肿瘤内蓄积中的作用。

Involvement of Caveolin-1-mediated transcytosis in the intratumoral accumulation of liposomes.

机构信息

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan.

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan.

出版信息

Biochem Biophys Res Commun. 2020 Apr 30;525(2):313-318. doi: 10.1016/j.bbrc.2020.02.086. Epub 2020 Feb 20.

Abstract

For achieving efficient cancer treatment, it is important to elucidate the mechanism responsible for the accumulation of nanoparticles in tumor tissue. Recent studies suggest that nanoparticles are not delivered merely through gaps between tumor endothelial cells. We previously reported that the maturation of the vascular structure by the vascular endothelial cell growth factor receptor 2 (VEGFR2) using a previously developed siRNA delivery technology (RGD-MEND) significantly enhanced the accumulation of nanoparticles in types of cancers that area vessel-rich (renal cell carcinoma). This result was completely inconsistent with the generally accepted theory of the enhanced permeability and retention (EPR) effect. We hypothesized that a caveolin-1 (Cav1)-mediated transcellular route would be involved with the penetration of nanoparticles into tumor vasculature. To reveal the exact mechanism responsible for this enhancement, we observed the delivery of long-circulating liposomes (LPs) after Cav1 was co-suppressed by RGD-MEND with VEGFR2. The enhanced delivery of LPs by siRNA against VEGFR2 (siVEGFR2) was accompanied by the elevated expression of the Cav1 protein. In addition, Cav1 knockdown by siRNA against Cav1 (siCav1) canceled the enhanced delivery of LPs by siVEGFR2. The injection of siCav1 had no effect on the formation of alpha smooth muscle actin or vascular endothelial cell adhesion molecules. These results suggest that a Cav1-induced transcellular route and not a paracellular route, at least partially, contributes to the accumulation of nanoparticles in tumors.

摘要

为了实现有效的癌症治疗,阐明导致纳米颗粒在肿瘤组织中积累的机制非常重要。最近的研究表明,纳米颗粒并非仅仅通过肿瘤内皮细胞之间的间隙传递。我们之前报道,使用先前开发的 siRNA 递药技术(RGD-MEND)通过血管内皮细胞生长因子受体 2(VEGFR2)成熟血管结构,可显著增强在富含血管的(肾细胞癌)等类型癌症中纳米颗粒的积累。这一结果与普遍接受的增强型渗透和保留(EPR)效应理论完全不一致。我们假设 Cav1 介导的细胞间途径会涉及纳米颗粒穿透肿瘤血管。为了揭示这种增强的精确机制,我们观察了在与 VEGFR2 共抑制的情况下,用 RGD-MEND 共抑制 Cav1 后长循环脂质体(LPs)的递药。针对 VEGFR2 的 siRNA(siVEGFR2)增强了 LPs 的递药,同时 Cav1 蛋白的表达也升高了。此外,针对 Cav1 的 siRNA(siCav1)敲低可使 siVEGFR2 增强的 LPs 递药作用消失。siCav1 的注射对α平滑肌肌动蛋白或血管内皮细胞黏附分子的形成没有影响。这些结果表明,Cav1 诱导的细胞间途径至少部分地有助于纳米颗粒在肿瘤中的积累,而不是细胞旁途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验